封面
市场调查报告书
商品编码
1738276

干眼症治疗市场-全球产业规模、份额、趋势、机会和预测,按适应症、产品类型、剂型、类型、配销通路、地区和竞争情况划分,2020 年至 2030 年预测

Dry Eye Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Indication, By Product Type, By Dosage Form, By Type, By Distribution Channel, By Region, and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球干眼症治疗市场价值为 63.1 亿美元,预计到 2030 年将达到 91.5 亿美元,预测期内的复合年增长率为 6.39%。这种增长是由于与类风湿性关节炎、狼疮和甲状腺疾病等自体免疫疾病相关的干眼症盛行率不断上升所致。越来越多的创新药物疗法和眼药水配方获得批准,加上干眼症管理研发的进步,正在推动市场扩张。促进泪液分泌的鼻内泪液神经刺激装置等技术进步也正在促进需求。此外,越来越多的新市场进入者涌入,加速了监管部门的批准并扩大了治疗的可及性。然而,公众意识有限和诊断不足仍然是市场渗透的重大障碍。

市场概览
预测期 2026-2030
2024年市场规模 63.1亿美元
2030年市场规模 91.5亿美元
2025-2030 年复合年增长率 6.39%
成长最快的领域 水样缺乏性干眼症
最大的市场 北美洲

关键市场驱动因素

老年人口增长及与年龄相关的眼部疾病

主要市场挑战

患者认知度低和诊断不足

主要市场趋势

人工智慧与诊断技术的融合

目录

第 1 章:产品概述

第二章:研究方法

第三章:执行摘要

第四章:顾客之声

第五章:临床试验分析

第六章:全球干眼症治疗市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依适应症(蒸发过强型干眼症、水样液缺乏型干眼症)
    • 依产品类型(环孢素、外用皮质类固醇、人工泪液、泪点塞、其他)
    • 按剂型(凝胶、眼药水、胶囊及药片、眼药水、药膏)
    • 依类型(处方药、非处方药)
    • 按配销通路(医院药房、零售药房、网路药房)
    • 按地区
    • 按公司分类(2024)
  • 市场地图
    • 按适应症
    • 依产品类型
    • 按剂型
    • 按类型
    • 按配销通路
    • 按地区

第七章:北美干眼症治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美:国家分析
    • 美国
    • 加拿大
    • 墨西哥

第八章:欧洲干眼症治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲:国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第九章:亚太干眼症治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区:国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第十章:南美洲干眼症治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲:国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 11 章:中东和非洲干眼症治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA:国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 12 章:市场动态

  • 驱动程式
  • 挑战

第十三章:市场趋势与发展

  • 最新动态
  • 併购
  • 产品发布

第 14 章:全球干眼症治疗市场:SWOT 分析

第 15 章:波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品/服务的威胁

第 16 章:竞争格局

  • Johnson & Johnson Services, Inc.
  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Novartis AG
  • Sun Pharmaceuticals Industries Limited
  • Santen Pharmaceutical Co., Ltd.
  • Otsuka Pharmaceutical Co., Ltd.
  • Oyster Point Pharma, Inc.
  • Alcon Inc.
  • GlaxoSmithKline plc

第 17 章:策略建议

第18章调查会社について・免责事项

简介目录
Product Code: 14428

The Global Dry Eye Syndrome Treatment Market was valued at USD 6.31 billion in 2024 and is projected to reach USD 9.15 billion by 2030, growing at a CAGR of 6.39% during the forecast period. This growth is driven by the increasing prevalence of dry eye conditions linked to autoimmune diseases such as rheumatoid arthritis, lupus, and thyroid disorders. Rising approvals of innovative drug therapies and eye drop formulations, coupled with advancements in R&D for dry eye management, are propelling market expansion. Technological progress, such as intranasal tear neurostimulation devices that promote tear production, is also fostering demand. Additionally, a growing influx of new market entrants is accelerating regulatory approvals and broadening treatment accessibility. However, limited public awareness and underdiagnosis remain significant hurdles for market penetration.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 6.31 Billion
Market Size 2030USD 9.15 Billion
CAGR 2025-20306.39%
Fastest Growing SegmentAqueous Deficient Dry Eye Syndrome
Largest MarketNorth America

Key Market Drivers

Rising Geriatric Population and Age-Related Ocular Conditions

The expanding elderly demographic is a key driver for the global dry eye syndrome treatment market, as aging is closely linked to reduced tear production and gland function. Data from the United Nations Department of Economic and Social Affairs indicates that the global population aged 65 and over will exceed 1.6 billion by 2050. Older individuals are more susceptible to dry eye symptoms due to age-related degradation of tear film and meibomian gland health. In the United States, nearly 15% of adults over 50 report symptoms of dry eye, particularly among women. This demographic trend is creating sustained demand for targeted dry eye treatments, especially in developed regions where aging populations are most pronounced.

Key Market Challenges

Low Patient Awareness and Underdiagnosis

Despite its growing prevalence, dry eye syndrome remains significantly underdiagnosed due to limited public awareness and misconceptions about symptoms. Many individuals attribute discomfort to temporary factors and delay seeking professional care, leading to untreated cases. According to the U.S. National Eye Institute, a majority of dry eye sufferers remain undiagnosed, particularly in lower-income regions with limited access to specialized care. Additionally, inconsistent diagnostic standards and limited practitioner training contribute to misclassification and reliance on over-the-counter products. Cultural attitudes and the low prioritization of eye health in some countries further exacerbate this issue, restricting treatment adoption and hindering market growth.

Key Market Trends

Integration of Artificial Intelligence and Diagnostic Technologies

Artificial intelligence and advanced diagnostic tools are transforming how dry eye syndrome is detected and managed. AI-based imaging systems are increasingly used to assess tear stability, gland function, and ocular surface conditions with higher accuracy than manual observation. These tools are essential in streamlining diagnostics, particularly in teleophthalmology and high-volume clinical settings. Regulatory and funding support, such as the FDA's approval of AI diagnostic tools and the NIH's investments in healthcare AI, are accelerating adoption. Countries like Japan and South Korea are implementing AI within smart hospitals to enhance diagnostic efficiency. This technological integration supports early intervention, improves treatment outcomes, and lowers long-term healthcare expenditures related to untreated dry eye.

Key Market Players

  • Johnson & Johnson Services, Inc.
  • AbbVie Inc.
  • Bausch Health Companies Inc.
  • Novartis AG
  • Sun Pharmaceuticals Industries Limited
  • Santen Pharmaceutical Co., Ltd.
  • Otsuka Pharmaceutical Co., Ltd.
  • Oyster Point Pharma, Inc.
  • Alcon Inc.
  • GlaxoSmithKline plc

Report Scope:

In this report, the Global Dry Eye Syndrome Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dry Eye Syndrome Treatment Market, By Indication:

  • Evaporative Dry Eye Syndrome
  • Aqueous Deficient Dry Eye Syndrome

Dry Eye Syndrome Treatment Market, By Product Type:

  • Cyclosporine
  • Topical Corticosteroids
  • Artificial Tears
  • Punctal Plugs
  • Others

Dry Eye Syndrome Treatment Market, By Dosage Form:

  • Gels
  • Eye Solutions
  • Capsules & Tablets
  • Eye Drops
  • Ointments

Dry Eye Syndrome Treatment Market, By Type:

  • Prescription
  • Over The Counter

Dry Eye Syndrome Treatment Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Dry Eye Syndrome Treatment Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Japan
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dry Eye Syndrome Treatment Market.

Available Customizations:

Global Dry Eye Syndrome Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Type
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Dry Eye Syndrome Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication (Evaporative Dry Eye Syndrome, Aqueous Deficient Dry Eye Syndrome)
    • 6.2.2. By Product Type (Cyclosporine, Topical Corticosteroids, Artificial Tears, Punctal Plugs, Others)
    • 6.2.3. By Dosage Form (Gels, Eye Solutions, Capsules & Tablets, Eye Drops, Ointments)
    • 6.2.4. By Type (Prescription, Over The Counter)
    • 6.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 6.2.6. By Region
    • 6.2.7. By Company (2024)
  • 6.3. Market Map
    • 6.3.1. By Indication
    • 6.3.2. By Product Type
    • 6.3.3. By Dosage Form
    • 6.3.4. By Type
    • 6.3.5. By Distribution Channel
    • 6.3.6. By Region

7. North America Dry Eye Syndrome Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Product Type
    • 7.2.3. By Dosage Form
    • 7.2.4. By Type
    • 7.2.5. By Distribution Channel
    • 7.2.6. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Dry Eye Syndrome Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Product Type
        • 7.3.1.2.3. By Dosage Form
        • 7.3.1.2.4. By Type
        • 7.3.1.2.5. By Distribution Channel
    • 7.3.2. Canada Dry Eye Syndrome Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Product Type
        • 7.3.2.2.3. By Dosage Form
        • 7.3.2.2.4. By Type
        • 7.3.2.2.5. By Distribution Channel
    • 7.3.3. Mexico Dry Eye Syndrome Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Product Type
        • 7.3.3.2.3. By Dosage Form
        • 7.3.3.2.4. By Type
        • 7.3.3.2.5. By Distribution Channel

8. Europe Dry Eye Syndrome Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Product Type
    • 8.2.3. By Dosage Form
    • 8.2.4. By Type
    • 8.2.5. By Distribution Channel
    • 8.2.6. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Dry Eye Syndrome Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Product Type
        • 8.3.1.2.3. By Dosage Form
        • 8.3.1.2.4. By Type
        • 8.3.1.2.5. By Distribution Channel
    • 8.3.2. Germany Dry Eye Syndrome Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Product Type
        • 8.3.2.2.3. By Dosage Form
        • 8.3.2.2.4. By Type
        • 8.3.2.2.5. By Distribution Channel
    • 8.3.3. United Kingdom Dry Eye Syndrome Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Product Type
        • 8.3.3.2.3. By Dosage Form
        • 8.3.3.2.4. By Type
        • 8.3.3.2.5. By Distribution Channel
    • 8.3.4. Italy Dry Eye Syndrome Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Product Type
        • 8.3.4.2.3. By Dosage Form
        • 8.3.4.2.4. By Type
        • 8.3.4.2.5. By Distribution Channel
    • 8.3.5. Spain Dry Eye Syndrome Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Product Type
        • 8.3.5.2.3. By Dosage Form
        • 8.3.5.2.4. By Type
        • 8.3.5.2.5. By Distribution Channel

9. Asia-Pacific Dry Eye Syndrome Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Product Type
    • 9.2.3. By Dosage Form
    • 9.2.4. By Type
    • 9.2.5. By Distribution Channel
    • 9.2.6. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Dry Eye Syndrome Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Product Type
        • 9.3.1.2.3. By Dosage Form
        • 9.3.1.2.4. By Type
        • 9.3.1.2.5. By Distribution Channel
    • 9.3.2. India Dry Eye Syndrome Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Product Type
        • 9.3.2.2.3. By Dosage Form
        • 9.3.2.2.4. By Type
        • 9.3.2.2.5. By Distribution Channel
    • 9.3.3. Japan Dry Eye Syndrome Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Product Type
        • 9.3.3.2.3. By Dosage Form
        • 9.3.3.2.4. By Type
        • 9.3.3.2.5. By Distribution Channel
    • 9.3.4. South Korea Dry Eye Syndrome Treatment Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Indication
        • 9.3.4.2.2. By Product Type
        • 9.3.4.2.3. By Dosage Form
        • 9.3.4.2.4. By Type
        • 9.3.4.2.5. By Distribution Channel
    • 9.3.5. Australia Dry Eye Syndrome Treatment Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Indication
        • 9.3.5.2.2. By Product Type
        • 9.3.5.2.3. By Dosage Form
        • 9.3.5.2.4. By Type
        • 9.3.5.2.5. By Distribution Channel

10. South America Dry Eye Syndrome Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Product Type
    • 10.2.3. By Dosage Form
    • 10.2.4. By Type
    • 10.2.5. By Distribution Channel
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Dry Eye Syndrome Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Product Type
        • 10.3.1.2.3. By Dosage Form
        • 10.3.1.2.4. By Type
        • 10.3.1.2.5. By Distribution Channel
    • 10.3.2. Argentina Dry Eye Syndrome Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Product Type
        • 10.3.2.2.3. By Dosage Form
        • 10.3.2.2.4. By Type
        • 10.3.2.2.5. By Distribution Channel
    • 10.3.3. Colombia Dry Eye Syndrome Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Product Type
        • 10.3.3.2.3. By Dosage Form
        • 10.3.3.2.4. By Type
        • 10.3.3.2.5. By Distribution Channel

11. Middle East and Africa Dry Eye Syndrome Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Indication
    • 11.2.2. By Product Type
    • 11.2.3. By Dosage Form
    • 11.2.4. By Type
    • 11.2.5. By Distribution Channel
    • 11.2.6. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Dry Eye Syndrome Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Indication
        • 11.3.1.2.2. By Product Type
        • 11.3.1.2.3. By Dosage Form
        • 11.3.1.2.4. By Type
        • 11.3.1.2.5. By Distribution Channel
    • 11.3.2. Saudi Arabia Dry Eye Syndrome Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Indication
        • 11.3.2.2.2. By Product Type
        • 11.3.2.2.3. By Dosage Form
        • 11.3.2.2.4. By Type
        • 11.3.2.2.5. By Distribution Channel
    • 11.3.3. UAE Dry Eye Syndrome Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Indication
        • 11.3.3.2.2. By Product Type
        • 11.3.3.2.3. By Dosage Form
        • 11.3.3.2.4. By Type
        • 11.3.3.2.5. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Global Dry Eye Syndrome Treatment Market: SWOT Analysis

15. Porters Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products/Services

16. Competitive Landscape

  • 16.1. Johnson & Johnson Services, Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (As Reported)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. AbbVie Inc.
  • 16.3. Bausch Health Companies Inc.
  • 16.4. Novartis AG
  • 16.5. Sun Pharmaceuticals Industries Limited
  • 16.6. Santen Pharmaceutical Co., Ltd.
  • 16.7. Otsuka Pharmaceutical Co., Ltd.
  • 16.8. Oyster Point Pharma, Inc.
  • 16.9. Alcon Inc.
  • 16.10. GlaxoSmithKline plc

17. Strategic Recommendations

18. About Us & Disclaimer